Future development of non-selective Tyk2 inhibitors will be focused on diseases where therapeutic benefit outweighs potential safety concerns, as illustrated by the current indications pursued for brepocitinib (SLE, dermatomyositis, and uveitis). This evidence concerns the gene TYK2 and systemic lupus erythematosus.